News & Updates
Filter by Specialty:
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
25 Oct 2022
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
23 Oct 2022
Circulating T cells tied to CVD risk in people with HIV infection
Subsets of peripheral circulating CD4 T cell among people with HIV infection (PWH) are predictive of incident cardiovascular disease (CVD), including heart failure and atherosclerotic CVD, reveals a study.
Circulating T cells tied to CVD risk in people with HIV infection
20 Oct 2022
Beta-blocker shows potential for diabetic foot ulcers
A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).
Beta-blocker shows potential for diabetic foot ulcers
20 Oct 2022
Topical antibiotics work well against acute infectious conjunctivitis in children
Treatment with topical antibiotics in children with acute infectious conjunctivitis shortens time to clinical cure and helps resolve symptoms as early as 3 days, as reported in a study.
Topical antibiotics work well against acute infectious conjunctivitis in children
17 Oct 2022
Pre-DAA IL-1β can predict HBV reactivation in HCV
Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.
Pre-DAA IL-1β can predict HBV reactivation in HCV
14 Oct 2022
Kidney transplant recipients see lower IgG production after COVID-19 jab
Vaccination against COVID-19 seems to be less effective among kidney transplant recipients, according to a recent study. Cessation or reduction of immunosuppressive treatments may help increase the production of immunoglobulin (Ig)G in these patients.